New device aims to bridge heart failure patients to Life-Saving pump

NCT ID NCT03836482

Recruiting now Disease control Sponsor: SeaStar Medical Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a device that filters out overactive immune cells from the blood to reduce inflammation in patients with severe heart failure and worsening kidney function. Twenty ICU patients will receive 4-hour treatments daily for up to 6 days. The goal is to see if it safely improves heart and kidney function enough to make them eligible for a heart pump.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Selective Cytopheretic Device (SCD)
What this could lead to: If it works, this device could help stabilize heart and kidney function, making more patients eligible for a life-saving heart pump.
What could go wrong: This is a very early, small study with only 20 patients. The device is experimental, and it may not improve outcomes or could cause complications like infection or bleeding.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE ON CHRONIC SYSTOLIC CONGESTIVE HEART FAILURE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cardio-renal syndrome congestive heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE ON CHRONIC SYSTOLIC CONGESTIVE HEART FAILURE CARDIORENAL SYNDROME

Contacts and locations

Show contact details

Locations

University of Michigan
RECRUITING

Ann Arbor, Michigan, 48109, United States

Contact Phone: •••-•••-••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.